2. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Antibody-drug Conjugate/ADC Related
  3. ROR Radionuclide-Drug Conjugates (RDCs)
  4. DP1 peptide

DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

DP1 peptide

DP1 peptide Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

DP1 peptide Related Antibodies

Top Publications Citing Use of Products

View All ROR Isoform Specific Products:

View All Isoforms
RORγ RORα RORβ

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer[1].

IC50 & Target[1]

RORα

74.9 nM (Ki)

In Vitro

[68Ga]Ga-DP1 (3.125-400 nM; 1 h) binds to ROR1 in MC38 cells with high affinity, with a Kd value of 74.9 nM[1].
[68Ga]Ga-DP1) (10-60 min) shows significantly higher ROR1-specific uptake in MC38 cells than radiolabeled DP2 and DP3, with its uptake accounting for 7.26% of the total activity after 30 min of incubation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DP1 peptide Related Antibodies
In Vivo

[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) achieves detectable tumor uptake in HepG2 subcutaneous xenograft models and can be used to visualize ROR1 expression[1].
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) achieves detectable tumor uptake in the A549 subcutaneous xenograft model, enabling visualization of ROR1 expression[1].
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) exhibits specific, measurable tumor uptake in the MC38 allograft model, with a favorable tumor-to-muscle ratio at 60 min post-injection. Moreover, excess PR7 blocks its uptake, confirming the specificity for ROR1[1].
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) achieves detectable specific tumor uptake in the B16F10 allograft model, with uptake levels lower than those in the MC38 model, which is consistent with the lower expression level of ROR1 in B16F10 tumors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft model)[1]
Dosage: 7.4 MBq
Administration: i.v.; single dose
Result: Reached tumor uptake of 0.52% ID/g at 30 min postinjection.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
Animal Model: BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft model)[1]
Dosage: 7.4 MBq
Administration: i.v.; single dose
Result: Reached tumor uptake of 0.50% ID/g at 30 min postinjection.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
Animal Model: C57BL/6 (male, 6-8 weeks old, subcutaneous allograft model)[1]
Dosage: 7.4 MBq; 100 μg PR7 (blocking dose)
Administration: i.v.; single dose; i.v.; single coinjection (blocking dose)
Result: Reached tumor uptake of 0.65% ID/g at 30 min postinjection and 0.94% ID/g at 60 min postinjection.
Showed significantly reduced tumor uptake (P < 0.001) in the PR7 blocking group.
Reached kidney accumulation of 27.90% ID/g at 30 min postinjection and 20.91% ID/g at 60 min postinjection.
Achieved a tumor-to-muscle ratio of 2.47 at 60 min postinjection.
Animal Model: C57BL/6 (male, 6-8 weeks old, subcutaneous allograft model)[1]
Dosage: 7.4 MBq; 100 μg PR7 (blocking dose)
Administration: i.v.; single dose; i.v.; single coinjection (blocking dose)
Result: Reached tumor uptake of 0.40% ID/g at 30 min postinjection, which was significantly lower than uptake in MC38 tumors.
Showed significantly reduced tumor uptake in the PR7 blocking group.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
Molecular Weight

2519.63

Formula

C112H159N29O38
Sequence

Tetraxetan-Ser-Asp-Ile-Asn-Asp-Arg-Gln-Ile-Pro-Gly-Tyr-Ser-Thr-Tyr-Trp-Gly-Asp-Phe-NH2
Sequence Shortening

Tetraxetan-SDINDRQIPGYSTYWGDF-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DP1 peptide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DP1 peptideRORRadionuclide-Drug Conjugates (RDCs)RAR-related orphan receptormelanomacolorectal cancerchronic lymphocytic leukemiaROR1MC38 cellshepatocellular carcinomalung adenocarcinomaglioblastoma multiformebreast cancerHepG2 subcutaneous xenograft modelsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DP1 peptide
Cat. No.:
HY-P11858
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.